Fulvestrant vs Palazestrant

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HR+/HER2- Metastatic Breast Cancer

Shared mechanism: Estrogen receptor · full HR+/HER2- Metastatic Breast Cancer pipeline

Fulvestrant · Faslodex

Marketed by AstraZeneca

Approved in HR+/HER2- Metastatic Breast Cancersmall molecule
Partial signal

NCT00635713 · Phase 3 · completed

The trial randomized an estimated 588 participants and used double blinding to compare two active treatment groups: fulvestrant 125 mg plus anastrozole versus fulvestrant 250 mg plus anastrozole. Its primary endpoint was time to tumor progression, a clinical outcome. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

ClinicalTrials.gov records both arms as fulvestrant plus anastrozole. The published North American Trial 0021 (Osborne 2002) randomized fulvestrant 250 mg monthly against anastrozole 1 mg daily, double-blind and double-dummy.

Next expected readout: December 2026 · NCT07163481 (registry estimate)

Reported efficacy

Comparison of Progression-Free Survival (PFS) in Patients Treated With Fulvestrant With Those Treated With Anastrozole (Baseline RECIST 1.1 assessments (Day 0) and then every 12 weeks until the earliest of disease progression evident, patient dies or has surgery/radiotherapy for their disease (up to approximately 38 months)): Comparison of Progression-Free Survival (PFS) in Patients Treated With Fulvestrant With Those Treated With Anastrozole (Baseline RECIST 1.1 assessments (Day 0) and then every 12 weeks until the earliest of disease progression evident, patient dies or has surgery/radiotherapy for their disease (up to approximately 38 months)): Fulvestrant 500 mg 16.6 Months (95% CI 13.83 to 20.99) vs Anastrozole 1 mg 13.8 Months (95% CI 11.99 to 16.59) (met)

Result source: NCT01602380

Palazestrant

Developed by Olema Pharmaceuticals, Inc.

Phase 3 in HR+/HER2- Metastatic Breast Cancersmall molecule
Weak signal

NCT04505826 · Phase 1/2 · completed

The study was nonrandomized, unblinded, and single-arm, with participants receiving OP-1250 at sequential dose levels and no placebo or active comparator. Its results were descriptive rather than a formal comparative test: dose-limiting toxicities were 0/42 during dose escalation, while confirmed partial responses included 4/62 participants at 120 mg once daily; therefore, the primary outcomes were not formally met or missed against a control.

Next expected readout: December 2027 · NCT05508906 (registry estimate)

No aligned efficacy figure on record for this race.

Results for HR+/HER2- Metastatic Breast Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointFulvestrantPalazestrant
PFS, median4.7 vs 3.8+0.9 vs placebon 146NCT00390455
17 other results
—Trial running · NCT06016738
OS, median29.9 vs 26.4+3.5 vs placebon 146NCT00390455
10 other results
—Trial running · NCT06016738
ORR20% vs 9%+11 vs placebon 101NCT00390455
9 other results
  • 13% vs 23% n 32 · Phase 3 · secondary NCT00390455
  • 38% vs 17% n 8 · Phase 3 · secondary NCT00390455
  • 46.1% vs 44.9% 500 mg · n 193 · Phase 3 · secondary NCT01602380
  • 29.9% n 45 · Phase 2 · primary NCT02860000
  • 32.9% vs 13.9% 150 mg + 8 mg/kg + 500 mg · n 79 · Phase 2 · secondary NCT02675231
  • 13.9% vs 13.9% 150 mg + 8 mg/kg · n 79 · Phase 2 · secondary NCT02675231
  • 19.3% n 119 · Phase 2 · secondary NCT03056755
  • 17.5% n 114 · Phase 2 · secondary NCT03056755
  • 25.2% n 115 · Phase 2 · secondary NCT03056755
—Trial running · NCT06016738
Clinical benefit rate78.3% vs 74.1%vs Anastrozole500 mg · n 230NCT01602380
9 other results
  • 55% vs 55.1% n 258 · Phase 3 · secondary NCT00256698
  • 70% n 345 · Phase 3 · secondary NCT00075764
  • 73% n 349 · Phase 3 · secondary NCT00075764
  • 58.2% vs 38% 150 mg + 8 mg/kg + 500 mg · n 79 · Phase 2 · secondary NCT02675231
  • 45.6% vs 38% 150 mg + 8 mg/kg · n 79 · Phase 2 · secondary NCT02675231
  • 28.9% wk 24 · n 45 · Phase 2 · secondary NCT02860000
  • 46.2% n 119 · Phase 2 · secondary NCT03056755
  • 35.1% n 114 · Phase 2 · secondary NCT03056755
  • 38.3% n 115 · Phase 2 · secondary NCT03056755
—Trial running · NCT06016738

PFS, median

Fulvestrant
4.7 vs 3.8+0.9 vs placebon 146NCT00390455
17 other results
Palazestrant
—Trial running · NCT06016738

OS, median

Fulvestrant
29.9 vs 26.4+3.5 vs placebon 146NCT00390455
10 other results
Palazestrant
—Trial running · NCT06016738

ORR

Fulvestrant
20% vs 9%+11 vs placebon 101NCT00390455
9 other results
  • 13% vs 23% n 32 · Phase 3 · secondary NCT00390455
  • 38% vs 17% n 8 · Phase 3 · secondary NCT00390455
  • 46.1% vs 44.9% 500 mg · n 193 · Phase 3 · secondary NCT01602380
  • 29.9% n 45 · Phase 2 · primary NCT02860000
  • 32.9% vs 13.9% 150 mg + 8 mg/kg + 500 mg · n 79 · Phase 2 · secondary NCT02675231
  • 13.9% vs 13.9% 150 mg + 8 mg/kg · n 79 · Phase 2 · secondary NCT02675231
  • 19.3% n 119 · Phase 2 · secondary NCT03056755
  • 17.5% n 114 · Phase 2 · secondary NCT03056755
  • 25.2% n 115 · Phase 2 · secondary NCT03056755
Palazestrant
—Trial running · NCT06016738

Clinical benefit rate

Fulvestrant
78.3% vs 74.1%vs Anastrozole500 mg · n 230NCT01602380
9 other results
  • 55% vs 55.1% n 258 · Phase 3 · secondary NCT00256698
  • 70% n 345 · Phase 3 · secondary NCT00075764
  • 73% n 349 · Phase 3 · secondary NCT00075764
  • 58.2% vs 38% 150 mg + 8 mg/kg + 500 mg · n 79 · Phase 2 · secondary NCT02675231
  • 45.6% vs 38% 150 mg + 8 mg/kg · n 79 · Phase 2 · secondary NCT02675231
  • 28.9% wk 24 · n 45 · Phase 2 · secondary NCT02860000
  • 46.2% n 119 · Phase 2 · secondary NCT03056755
  • 35.1% n 114 · Phase 2 · secondary NCT03056755
  • 38.3% n 115 · Phase 2 · secondary NCT03056755
Palazestrant
—Trial running · NCT06016738
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety

Coverage. Fulvestrant: 5 of 5 rows · Palazestrant: 4 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricFulvestrantPalazestrant
ORR
event count · % of participants
No placebo or comparator arm
28.1% (n=57)*500 mga,b,c,d
NCT01300351 · Phase 3 · registry result, not featured evidence · converted to % from 16 patients as posted
3 other source trials
33.3% (n=54)*
NCT03007979 · Phase 2 · registry result, not featured evidence · combination · converted to % from 18 Participants as posted
30% (n=10)*
NCT01670877 · Phase 2 · registry result, not featured evidence · combination · converted to % from 3 Participants as posted
23.8% (n=21)*
NCT01670877 · Phase 2 · registry result, not featured evidence · combination · converted to % from 5 Participants as posted
0% (n=4)*300 mg QDe,a,b,c,d
NCT04505826 · Phase 1/2 · converted to % from 0 Participants as posted
show 7 more doses
0% (n=4)*210 mg QD
NCT04505826 · Phase 1/2 · converted to % from 0 Participants as posted
0% (n=1)*150 mg QD
NCT04505826 · Phase 1/2 · converted to % from 0 Participants as posted
0% (n=5)*120 mg QD
NCT04505826 · Phase 1/2 · converted to % from 0 Participants as posted
6.5% (n=62)*120 mg QD
NCT04505826 · Phase 1/2 · converted to % from 4 Participants as posted
0% (n=4)*90 mg QD
NCT04505826 · Phase 1/2 · converted to % from 0 Participants as posted
7.1% (n=28)*60 mg QD
NCT04505826 · Phase 1/2 · converted to % from 2 Participants as posted
0% (n=5)*30 mg QD
NCT04505826 · Phase 1/2 · converted to % from 0 Participants as posted
Dropout rate
89.1%500 mgf
NCT01602380 · Phase 3 · combination
show 40 more results
47.5%
NCT05631795 · Phase 4 · registry result, not featured evidence · combination
31.7%Abemaciclib + Fulvestrant
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
21.2%Abemaciclib + NSAI
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
1.2%
NCT02447328 · Phase 4 · registry result, not featured evidence
0%Faslodex + Arimidex
NCT00253422 · Phase 3 · registry result, not featured evidence · combination
0%Faslodex + Placebo
NCT00253422 · Phase 3 · registry result, not featured evidence
n/a: no completion milestone
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
—Anastrozole
NCT00075764 · Phase 3 · registry result, not featured evidence
—Anastrozole & Fulvestrant
NCT00075764 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestoneArm I Anastrozole
NCT00075764 · Phase 3 · registry result, not featured evidence
n/a: no completion milestoneArm II Anastrozole and Fulvestrant
NCT00075764 · Phase 3 · registry result, not featured evidence · combination
21.6%
NCT00390455 · Phase 3 · registry result, not featured evidence
32.4%500 mg
NCT01300351 · Phase 3 · registry result, not featured evidence
64.7%
NCT00256698 · Phase 3 · registry result, not featured evidence · combination
0%
NCT02692755 · Phase 2/3 · registry result, not featured evidence · combination
1.1%
NCT03633331 · Phase 2 · registry result, not featured evidence · combination
87.5%
NCT04224272 · Phase 2 · registry result, not featured evidence · combination
8.2%
NCT02860000 · Phase 2 · registry result, not featured evidence · combination
99.2%Cohort A: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort A: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort A: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
100%Cohort B: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort B: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
92.1%Cohort C: Pre-treated With Systemi
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort C: Pre-treated With Systemi
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort C: Pre-treated With Systemi
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
10.1%150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
6.3%150 mg + 8 mg/kg + 500 mg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
1.8%
NCT03007979 · Phase 2 · registry result, not featured evidence · combination
1.6%
NCT02536742 · Phase 2 · registry result, not featured evidence
—Crossover: Neratinib + Fulvestrant
NCT01670877 · Phase 2 · registry result, not featured evidence · combination
9.1%Part II: Neratinib + Fulvestrant (
NCT01670877 · Phase 2 · registry result, not featured evidence · combination
12.5%Part II: Neratinib + Fulvestrant (
NCT01670877 · Phase 2 · registry result, not featured evidence · combination
3.4%Arm B: Fulvestrant + Bortezomib
NCT01142401 · Phase 2 · registry result, not featured evidence · combination
—Arm C: Crossover From Arm A at Pro
NCT01142401 · Phase 2 · registry result, not featured evidence · combination
0%
NCT02953860 · Phase 2 · registry result, not featured evidence · combination
0%
NCT01441947 · Phase 2 · registry result, not featured evidence · combination
69.6%500 mg
NCT00313170 · Phase 2 · registry result, not featured evidence
76.6%250 mg
NCT00313170 · Phase 2 · registry result, not featured evidence
66.7%250 mg + loading dose
NCT00313170 · Phase 2 · registry result, not featured evidence · combination
—300 mg QDf
NCT04505826 · Phase 1/2
show 14 more results
0%300 mg QD
NCT04505826 · Phase 1/2
—210 mg QD
NCT04505826 · Phase 1/2
0%210 mg QD
NCT04505826 · Phase 1/2
—150 mg QD
NCT04505826 · Phase 1/2
0%150 mg QD
NCT04505826 · Phase 1/2
—120 mg QD
NCT04505826 · Phase 1/2
—120 mg QD
NCT04505826 · Phase 1/2
0%120 mg QD
NCT04505826 · Phase 1/2
—90 mg QD
NCT04505826 · Phase 1/2
0%90 mg QD
NCT04505826 · Phase 1/2
—60 mg QD
NCT04505826 · Phase 1/2
0%60 mg QD
NCT04505826 · Phase 1/2
—30 mg QD
NCT04505826 · Phase 1/2
0%30 mg QD
NCT04505826 · Phase 1/2
Discontinued due to AEs
—500 mgf
NCT01602380 · Phase 3 · combination
show 40 more results
10%
NCT05631795 · Phase 4 · registry result, not featured evidence · combination
3.2%Abemaciclib + Fulvestrant
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
1.5%Abemaciclib + NSAI
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
—
NCT02447328 · Phase 4 · registry result, not featured evidence
—Faslodex + Arimidex
NCT00253422 · Phase 3 · registry result, not featured evidence · combination
—Faslodex + Placebo
NCT00253422 · Phase 3 · registry result, not featured evidence
2%
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
—Anastrozole
NCT00075764 · Phase 3 · registry result, not featured evidence
—Anastrozole & Fulvestrant
NCT00075764 · Phase 3 · registry result, not featured evidence · combination
1.4%Arm I Anastrozole
NCT00075764 · Phase 3 · registry result, not featured evidence
3.4%Arm II Anastrozole and Fulvestrant
NCT00075764 · Phase 3 · registry result, not featured evidence · combination
11.5%
NCT00390455 · Phase 3 · registry result, not featured evidence
0%500 mg
NCT01300351 · Phase 3 · registry result, not featured evidence
5%
NCT00256698 · Phase 3 · registry result, not featured evidence · combination
—
NCT02692755 · Phase 2/3 · registry result, not featured evidence · combination
—
NCT03633331 · Phase 2 · registry result, not featured evidence · combination
—
NCT04224272 · Phase 2 · registry result, not featured evidence · combination
—
NCT02860000 · Phase 2 · registry result, not featured evidence · combination
15.7%Cohort A: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort A: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort A: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
11.1%Cohort B: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort B: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
10.3%Cohort C: Pre-treated With Systemi
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort C: Pre-treated With Systemi
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort C: Pre-treated With Systemi
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
—150 mg + 8 mg/kg + 500 mg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
—
NCT03007979 · Phase 2 · registry result, not featured evidence · combination
—
NCT02536742 · Phase 2 · registry result, not featured evidence
—Crossover: Neratinib + Fulvestrant
NCT01670877 · Phase 2 · registry result, not featured evidence · combination
—Part II: Neratinib + Fulvestrant (
NCT01670877 · Phase 2 · registry result, not featured evidence · combination
—Part II: Neratinib + Fulvestrant (
NCT01670877 · Phase 2 · registry result, not featured evidence · combination
—Arm B: Fulvestrant + Bortezomib
NCT01142401 · Phase 2 · registry result, not featured evidence · combination
—Arm C: Crossover From Arm A at Pro
NCT01142401 · Phase 2 · registry result, not featured evidence · combination
—
NCT02953860 · Phase 2 · registry result, not featured evidence · combination
—
NCT01441947 · Phase 2 · registry result, not featured evidence · combination
0%500 mg
NCT00313170 · Phase 2 · registry result, not featured evidence
2.1%250 mg
NCT00313170 · Phase 2 · registry result, not featured evidence
3.9%250 mg + loading dose
NCT00313170 · Phase 2 · registry result, not featured evidence · combination
—300 mg QDf
NCT04505826 · Phase 1/2
show 14 more results
—300 mg QD
NCT04505826 · Phase 1/2
—210 mg QD
NCT04505826 · Phase 1/2
—210 mg QD
NCT04505826 · Phase 1/2
—150 mg QD
NCT04505826 · Phase 1/2
—150 mg QD
NCT04505826 · Phase 1/2
—120 mg QD
NCT04505826 · Phase 1/2
—120 mg QD
NCT04505826 · Phase 1/2
—120 mg QD
NCT04505826 · Phase 1/2
—90 mg QD
NCT04505826 · Phase 1/2
—90 mg QD
NCT04505826 · Phase 1/2
—60 mg QD
NCT04505826 · Phase 1/2
—60 mg QD
NCT04505826 · Phase 1/2
—30 mg QD
NCT04505826 · Phase 1/2
—30 mg QD
NCT04505826 · Phase 1/2
Serious AEs
17.1%500 mgf
NCT01602380 · Phase 3 · combination
show 40 more results
25%
NCT05631795 · Phase 4 · registry result, not featured evidence · combination
7.9%Abemaciclib + Fulvestrant
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
6.6%Abemaciclib + NSAI
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
11.1%
NCT02447328 · Phase 4 · registry result, not featured evidence
16.9%Faslodex + Arimidex
NCT00253422 · Phase 3 · registry result, not featured evidence · combination
13.8%Faslodex + Placebo
NCT00253422 · Phase 3 · registry result, not featured evidence
14.1%
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
6.2%Anastrozole
NCT00075764 · Phase 3 · registry result, not featured evidence
13.8%Anastrozole & Fulvestrant
NCT00075764 · Phase 3 · registry result, not featured evidence · combination
—Arm I Anastrozole
NCT00075764 · Phase 3 · registry result, not featured evidence
—Arm II Anastrozole and Fulvestrant
NCT00075764 · Phase 3 · registry result, not featured evidence · combination
8.5%
NCT00390455 · Phase 3 · registry result, not featured evidence
3.7%500 mg
NCT01300351 · Phase 3 · registry result, not featured evidence
15.6%
NCT00256698 · Phase 3 · registry result, not featured evidence · combination
—
NCT02692755 · Phase 2/3 · registry result, not featured evidence · combination
38%
NCT03633331 · Phase 2 · registry result, not featured evidence · combination
15.7%
NCT04224272 · Phase 2 · registry result, not featured evidence · combination
25%
NCT02860000 · Phase 2 · registry result, not featured evidence · combination
—Cohort A: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
29.1%Cohort A: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
0%Cohort A: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort B: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
38.1%Cohort B: Pre-treated With CDK 4/6
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
—Cohort C: Pre-treated With Systemi
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
30.2%Cohort C: Pre-treated With Systemi
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
30%Cohort C: Pre-treated With Systemi
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
19.5%150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
30.8%150 mg + 8 mg/kg + 500 mg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
27.8%
NCT03007979 · Phase 2 · registry result, not featured evidence · combination
73%
NCT02536742 · Phase 2 · registry result, not featured evidence
0%Crossover: Neratinib + Fulvestrant
NCT01670877 · Phase 2 · registry result, not featured evidence · combination
18.2%Part II: Neratinib + Fulvestrant (
NCT01670877 · Phase 2 · registry result, not featured evidence · combination
37.5%Part II: Neratinib + Fulvestrant (
NCT01670877 · Phase 2 · registry result, not featured evidence · combination
10.5%Arm B: Fulvestrant + Bortezomib
NCT01142401 · Phase 2 · registry result, not featured evidence · combination
18.5%Arm C: Crossover From Arm A at Pro
NCT01142401 · Phase 2 · registry result, not featured evidence · combination
6.3%
NCT02953860 · Phase 2 · registry result, not featured evidence · combination
23.1%
NCT01441947 · Phase 2 · registry result, not featured evidence · combination
8.7%500 mg
NCT00313170 · Phase 2 · registry result, not featured evidence
8.5%250 mg
NCT00313170 · Phase 2 · registry result, not featured evidence
18%250 mg + loading dose
NCT00313170 · Phase 2 · registry result, not featured evidence · combination
28.6%300 mg QDf
NCT04505826 · Phase 1/2
show 14 more results
—300 mg QD
NCT04505826 · Phase 1/2
28.6%210 mg QD
NCT04505826 · Phase 1/2
—210 mg QD
NCT04505826 · Phase 1/2
40%150 mg QD
NCT04505826 · Phase 1/2
—150 mg QD
NCT04505826 · Phase 1/2
19.3%120 mg QD
NCT04505826 · Phase 1/2
57.1%120 mg QD
NCT04505826 · Phase 1/2
—120 mg QD
NCT04505826 · Phase 1/2
33.3%90 mg QD
NCT04505826 · Phase 1/2
—90 mg QD
NCT04505826 · Phase 1/2
12.1%60 mg QD
NCT04505826 · Phase 1/2
—60 mg QD
NCT04505826 · Phase 1/2
0%30 mg QD
NCT04505826 · Phase 1/2
—30 mg QD
NCT04505826 · Phase 1/2
Most frequent reported AEs
500 mgf
arthralgia 18.4%
fatigue 12.7%
hot flush 11.4%
NCT01602380 · Phase 3 · combination
show 33 more results
hyperglycaemia 90%
stomatitis 37.5%
diarrhoea 35%
NCT05631795 · Phase 4 · registry result, not featured evidence · combination
diarrhoea 28.6%
anaemia 22.2%
fatigue 20.6%
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
diarrhoea 29.9%
neutropenia 24.8%
anaemia 23.4%
NCT04707196 · Phase 4 · registry result, not featured evidence · combination
myalgia 12.3%
nausea 12.3%
back pain 11.1%
NCT02447328 · Phase 4 · registry result, not featured evidence
lethargy 64.5%
arthralgia 42%
hot flush 37.2%
NCT00253422 · Phase 3 · registry result, not featured evidence · combination
lethargy 64.4%
vomiting 44.9%
arthralgia 43.6%
NCT00253422 · Phase 3 · registry result, not featured evidence
neutrophil count decreased 63.1%
fatigue 51%
hypertension 36.9%
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
fatigue (asthenia, lethargy, malaise) 60.2%
hot flashes/flushes 45.7%
pain - joint 45.1%
NCT00075764 · Phase 3 · registry result, not featured evidence
fatigue (asthenia, lethargy, malaise) 63.2%
hot flashes/flushes 54.3%
pain - joint 44%
NCT00075764 · Phase 3 · registry result, not featured evidence · combination
diarrhea 62.4% (placebo 21.9%)
fatigue 55.3% (placebo 53.3%)
rash acneiform 41.1% (placebo 4.4%)
NCT00390455 · Phase 3 · registry result, not featured evidence
500 mg
injection site reaction 11%
pyrexia 10.1%
fatigue 8.3%
NCT01300351 · Phase 3 · registry result, not featured evidence
arthralgia 11.7%
fatigue 10.5%
nausea 9%
NCT00256698 · Phase 3 · registry result, not featured evidence · combination
neutrophil count decreased 92.4%
white blood cell decreased 87%
fatigue 84.8%
NCT03633331 · Phase 2 · registry result, not featured evidence · combination
diarrhoea 92.2%
nausea 52.9%
stomatitis 41.2%
NCT04224272 · Phase 2 · registry result, not featured evidence · combination
fatigue 83.3%
anemia 62.5%
neutrophil count decreased 60.4%
NCT02860000 · Phase 2 · registry result, not featured evidence · combination
diarrhoea 64.6%
hyperglycaemia 59.8%
nausea 46.5%
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
asthenia 100%
blood creatinine increased 100%
diarrhoea 100%
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
diarrhoea 68.3%
hyperglycaemia 64.3%
nausea 54%
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
hyperglycaemia 67.5%
diarrhoea 54%
nausea 40.5%
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
diarrhoea 70%
hyperglycaemia 60%
fatigue 50%
NCT03056755 · Phase 2 · registry result, not featured evidence · combination
150 mg + 8 mg/kg
diarrhoea 77.9%
fatigue 53.2%
nausea 41.6%
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
150 mg + 8 mg/kg + 500 mg
diarrhoea 79.5%
fatigue 57.7%
nausea 48.7%
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
white blood cell count decreased 96.3%
neutrophil count decreased 87%
anemia 79.6%
NCT03007979 · Phase 2 · registry result, not featured evidence · combination
vomiting 60%
anorexia 40%
constipation 40%
NCT01670877 · Phase 2 · registry result, not featured evidence · combination
diarrhea 81.8%
anorexia 63.6%
aspartate aminotransferase increased 45.5%
NCT01670877 · Phase 2 · registry result, not featured evidence · combination
diarrhea 91.7%
fatigue 50%
nausea 50%
NCT01670877 · Phase 2 · registry result, not featured evidence · combination
hemoglobin - low 61.4%
thrombocytopenia 61.4%
nausea 59.6%
NCT01142401 · Phase 2 · registry result, not featured evidence · combination
hemoglobin - low 55.6%
thrombocytopenia 55.6%
diarrhea 51.9%
NCT01142401 · Phase 2 · registry result, not featured evidence · combination
fatigue 53.1%
nausea 50%
achiness 43.8%
NCT02953860 · Phase 2 · registry result, not featured evidence · combination
fatigue 76.9%
anorexia 61.5%
pain 53.8%
NCT01441947 · Phase 2 · registry result, not featured evidence · combination
500 mg
back pain 15.2%
fatigue 15.2%
nausea 15.2%
NCT00313170 · Phase 2 · registry result, not featured evidence
250 mg
nausea 25.5%
hot flush 19.1%
cough 12.8%
NCT00313170 · Phase 2 · registry result, not featured evidence
250 mg + loading dose
fatigue 22%
nausea 18%
back pain 16%
NCT00313170 · Phase 2 · registry result, not featured evidence · combination
300 mg QDf
nausea 85.7%
vomiting 71.4%
fatigue 57.1%
NCT04505826 · Phase 1/2
show 7 more results
210 mg QD
constipation 57.1%
nausea 57.1%
decreased appetite 42.9%
NCT04505826 · Phase 1/2
150 mg QD
nausea 80%
neutrophil count decreased 40%
vomiting 40%
NCT04505826 · Phase 1/2
120 mg QD
nausea 66.3%
fatigue 28.9%
vomiting 28.9%
NCT04505826 · Phase 1/2
120 mg QD
constipation 42.9%
hypokalaemia 42.9%
nausea 42.9%
NCT04505826 · Phase 1/2
90 mg QD
anxiety 33.3%
nausea 33.3%
photopsia 33.3%
NCT04505826 · Phase 1/2
60 mg QD
nausea 42.4%
fatigue 39.4%
headache 21.2%
NCT04505826 · Phase 1/2
30 mg QD
constipation 40%
diarrhoea 40%
fatigue 40%
NCT04505826 · Phase 1/2

Notes

  1. aTrial phases differ: Phase 1/2 versus Phase 3.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dThe assessment timepoint is not available for both results.
  5. eThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  6. fPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Fulvestrant

PFS 16.6 vs 13.8 Anastrozole months500 mg
time to event · months
NCT01602380 · Phase 3 · combination
show 9 more results
8.3 vs 5.7 Trastuzumab + Standard of Care Chemotherapy months150 mg + 8 mg/kg + 500 mg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
5.7 vs 5.7 Trastuzumab + Standard of Care Chemotherapy months150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
4.8 vs 3.5 Exemestane months
NCT00253422 · Phase 3 · registry result, not featured evidence
4.1 vs 3.5 Exemestane months
NCT00253422 · Phase 3 · registry result, not featured evidence · combination
7.5 vs 9.4 Capecitabine months
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
8 vs 10.6 Capecitabine months
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
4.7 vs 3.8 placebo months
NCT00390455 · Phase 3 · registry result, not featured evidence
4.1 vs 3.8 placebo months
NCT00390455 · Phase 3 · registry result, not featured evidence
5.9 vs 3.3 placebo months
NCT00390455 · Phase 3 · registry result, not featured evidence
All-cause Mortality 68.3% (n=230) vs 67.7% (n=232) Anastrozole500 mg
absolute value · percentage points
NCT01602380 · Phase 3 · combination
ORR 46.1% (n=193) vs 44.9% (n=196) Anastrozole500 mg
responder rate · % of participants
NCT01602380 · Phase 3 · combination
show 5 more results
32.9% (n=79) vs 13.9% (n=79) Trastuzumab + Standard of Care Chemotherapy150 mg + 8 mg/kg + 500 mg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
13.9% (n=79) vs 13.9% (n=79) Trastuzumab + Standard of Care Chemotherapy150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
20% (n=101) vs 9% (n=103) placebo
NCT00390455 · Phase 3 · registry result, not featured evidence
13% (n=32) vs 23% (n=32) placebo
NCT00390455 · Phase 3 · registry result, not featured evidence
38% (n=8) vs 17% (n=13) placebo
NCT00390455 · Phase 3 · registry result, not featured evidence
Duration of Response 20 vs 13.2 Anastrozole months500 mg
time to event · months
NCT01602380 · Phase 3 · combination
show 6 more results
12.5 vs NA Trastuzumab + Standard of Care Chemotherapy months150 mg + 8 mg/kg + 500 mg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
9.5 vs NA Trastuzumab + Standard of Care Chemotherapy months150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
10.2 vs 12.8 Exemestane months
NCT00253422 · Phase 3 · registry result, not featured evidence
8.7 vs 12.8 Exemestane months
NCT00253422 · Phase 3 · registry result, not featured evidence · combination
9.7 vs 11.2 Capecitabine months
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
22.3 vs 18.2 Anastrozole months
NCT00256698 · Phase 3 · registry result, not featured evidence · combination
Clinical Benefit 78.3% (n=230) vs 74.1% (n=232) Anastrozole500 mg
responder rate · % of participants
NCT01602380 · Phase 3 · combination
show 3 more results
58.2% (n=79) vs 38% (n=79) Trastuzumab + Standard of Care Chemotherapy150 mg + 8 mg/kg + 500 mg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
45.6% (n=79) vs 38% (n=79) Trastuzumab + Standard of Care Chemotherapy150 mg + 8 mg/kg
NCT02675231 · Phase 2 · registry result, not featured evidence · combination
55% (n=258) vs 55.1% (n=256) Anastrozole
NCT00256698 · Phase 3 · registry result, not featured evidence · combination
ORR 7.1% (n=226) vs 4.2% (n=239) Exemestane
event count · % of participants
NCT00253422 · Phase 3 · registry result, not featured evidence · converted to % from 16 Participants as posted
show 2 more results
7.3% (n=233) vs 4.2% (n=239) Exemestane*
NCT00253422 · Phase 3 · registry result, not featured evidence · combination · converted to % from 17 Participants as posted
22.8% (n=206) vs 29.4% (n=187) Capecitabine*
NCT02028507 · Phase 3 · registry result, not featured evidence · combination · converted to % from 47 Participants as posted
Clinical Benefit 24.3% (n=226) vs 23.8% (n=239) Exemestane
event count · % of participants
NCT00253422 · Phase 3 · registry result, not featured evidence · converted to % from 55 Participants as posted
show 2 more results
28.3% (n=233) vs 23.8% (n=239) Exemestane*
NCT00253422 · Phase 3 · registry result, not featured evidence · combination · converted to % from 66 Participants as posted
76.2% (n=206) vs 82.4% (n=187) Capecitabine*
NCT02028507 · Phase 3 · registry result, not featured evidence · combination · converted to % from 157 Participants as posted
Duration of Clinical Benefit 11.2 vs 12.2 Exemestane months
time to event · months
NCT00253422 · Phase 3 · registry result, not featured evidence
show 2 more results
11.5 vs 12.2 Exemestane months
NCT00253422 · Phase 3 · registry result, not featured evidence · combination
18.5 vs 18.1 Anastrozole months
NCT00256698 · Phase 3 · registry result, not featured evidence · combination
Time to Treatment Failure 3.8 vs 3.4 Exemestane months
time to event · months
NCT00253422 · Phase 3 · registry result, not featured evidence
show 2 more results
3.9 vs 3.4 Exemestane months
NCT00253422 · Phase 3 · registry result, not featured evidence · combination
12.4 vs 11.4 Anastrozole months
NCT00256698 · Phase 3 · registry result, not featured evidence · combination
Overall Survival 20.1 vs 22.5 Exemestane months
time to event · months
NCT00253422 · Phase 3 · registry result, not featured evidence
show 4 more results
20.2 vs 22.5 Exemestane months
NCT00253422 · Phase 3 · registry result, not featured evidence · combination
33.7 vs 32 Capecitabine months
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
29.9 vs 26.4 placebo months
NCT00390455 · Phase 3 · registry result, not featured evidence
37.8 vs 38.2 Anastrozole months
NCT00256698 · Phase 3 · registry result, not featured evidence · combination
EORTC QLQ-C30 Global Health Status 3.28 vs 1.97 Capecitabine score
absolute change · score
Global health status / QoL
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
EORTC QLQ-C30 Physical Functioning -1.73 vs -2.94 Capecitabine score
absolute change · score
Physical functioning
NCT02028507 · Phase 3 · registry result, not featured evidence · combination

+ 68 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Fulvestrant's landscape · Palazestrant's landscape